Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients

Background: Deferasirox (DFX) is commonly used to reduce the chronic iron overload (IO) in pediatric patients. However, the drug is characterized by a large pharmacokinetic variability and approximately 10% of patients may discontinue the treatment due to toxicities. Therefore, the present retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Galeotti, Laura, Ceccherini, Francesco, Fucile, Carmen, Marini, Valeria, Di Paolo, Antonello, Maximova, Natalia, Mattioli, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401444/
https://www.ncbi.nlm.nih.gov/pubmed/34452199
http://dx.doi.org/10.3390/pharmaceutics13081238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401444/
https://www.ncbi.nlm.nih.gov/pubmed/34452199
http://dx.doi.org/10.3390/pharmaceutics13081238

Ejemplares similares